Clinical trials
Solid Tumor clinical trials
Below are recruiting solid tumor clinical trials, each written for real people, not researchers. We’re tracking 1,689 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04900818RecruitingPhase 1
Givastomig for advanced solid cancers, including gastric and pancreas
This Phase 1 trial tests how safe and effective givastomig (TJ033721) is for advanced or metastatic solid tumors. It may help people whose cancer has grown despite standard treatment, or—if in the combination parts—specific cancers that meet certain lab test and tumor-marker requirements.
Orange, CaliforniaAges 18 years+ - NCT04901702RecruitingPhase 1/Phase 2
Onivyde plus talazoparib or temozolomide for resistant solid tumors
This trial tests whether adding Onivyde to either talazoparib or temozolomide can shrink or control hard-to-treat (refractory or recurring) cancers in children and young adults. It aims to find safer dosing first, then look at how well the treatment works—especially for Ewing sarcoma.
Palo Alto, CaliforniaAges 1–30 - NCT04930432RecruitingPhase 1/Phase 2
MCLA-129 for advanced EGFR- and MET-positive lung and other cancers
This early-phase trial tests MCLA-129, an antibody that targets EGFR and MET, in people with advanced cancers that have specific lab “biomarker” results. It’s for patients whose cancer has grown after standard treatments or can’t take standard treatment, with the goal of shrinking tumors and improving symptoms.
BaodingAges 18 years+ - NCT04977453RecruitingPhase 1/Phase 2
Study drug GI-101 alone or with immune or blood-pressure meds
This early-phase study tests GI-101 in people with advanced solid cancers. It may be given alone or combined with pembrolizumab or lenvatinib to see how safe it is and whether it can shrink tumors.
New York, New YorkAges 18 years+ - NCT05024214RecruitingPhase 1/Phase 2
Test of envafolimab plus lenvatinib for advanced solid tumors
This trial studies whether combining envafolimab (an anti-immune cancer medicine) with lenvatinib (a targeted pill) can shrink or control advanced cancers that have stopped responding to standard care. It may help people whose tumors are not curable with usual treatments, by testing a new combo and finding safe doses.
Bengbu, AnhuiAges 18 years+ - NCT05055609RecruitingPhase 1
Study drug TRE-515 for advanced solid tumors using PET scans
This Phase 1 trial tests how safe TRE-515 is, what dose can be used, and how the drug moves through the body, including using PET scans. It’s for adults with advanced solid cancers that have stopped responding to standard treatment.
Santa Monica, CaliforniaAges 18 years+ - NCT05076760RecruitingPhase 1
Study of a cancer-killing virus with standard treatments
This Phase 1 trial tests MEM-288, an oncolytic (cancer-killing) virus, either alone or combined with standard cancer medicines, in people with advanced solid tumors. It’s designed to see how the treatment works and how safe it is in different cancer types and after specific prior therapies.
Tampa, FloridaAges 18 years+ - NCT05086692RecruitingPhase 1/Phase 2
Beta-only IL-2 therapy for advanced solid tumors
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
San Diego, CaliforniaAges 18 years+ - NCT05118789RecruitingPhase 1/Phase 2
Study drug for ROS1-positive lung or solid tumors
This Phase 1/2 study tests zidesamtinib (NVL-520), a medicine meant to attack cancers that have a ROS1 genetic change. It’s for people with advanced or metastatic ROS1-rearranged NSCLC (lung cancer) and, in one group, other solid tumors.
Orange, CaliforniaAges 12 years+ - NCT05141474RecruitingEarly Phase 1
Personalized immune cell treatment for advanced cancers after failed therapy
This trial tests a personalized therapy made from your own immune cells (TIL) picked to match your tumor’s “neoantigens,” plus standard immune-boosting medicine (including IL-2). It’s for people with advanced epithelial or immune “resistant” solid tumors whose cancer has continued growing despite available treatments.
BarcelonaAges 18 years+ - NCT05144698RecruitingPhase 1/Phase 2
RAPA-201 cell therapy for certain advanced lung and head cancers
This Phase 1/2 trial tests RAPA-201, a personalized immune cell treatment made from your own T cells, for advanced solid tumors. It may help people whose cancer has come back after standard treatment and after an anti–PD-1/PD-L1 antibody.
Hackensack, New JerseyAges 18 years+ - NCT05216432RecruitingPhase 1
RLY-2608 for PIK3CA-mutant advanced solid tumors and breast cancer
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
Tucson, ArizonaAges 18 years+ - NCT05245500RecruitingPhase 1
Study drug for solid tumors with MTAP gene deletion
This Phase 1 trial studies MRTX1719, a new medicine, in solid tumors that have a missing MTAP gene (MTAP deletion). It aims to find the safest dose and check how the drug affects the tumor.
Phoenix, ArizonaAges 18 years+ - NCT05259709RecruitingPhase 1
Imaging test to map tumors in cancers on PD-1 therapy
This Phase 1 study tests a special imaging medicine to see how tumors and immune activity respond when you’re treated with cemiplimab (a PD-1 immunotherapy). It may help doctors better understand who benefits from PD-1 treatment by tracking where the medicine goes in the body.
GroningenAges 18 years+ - NCT05266612RecruitingPhase 1
Testing a cancer medicine for advanced solid tumors with HSV
This early (Phase 1) study tests VG2025, given alone or with nivolumab, in people with advanced solid cancers that have not responded to standard treatment. It may help by activating an immune response against cancer, especially in people who have HSV (herpes simplex virus) in their system.
Gilbert, ArizonaAges 18 years+ - NCT05269316RecruitingPhase 1/Phase 2
Early-phase study of IMP9064 for advanced solid tumors
This Phase 1/2 trial tests IMP9064, either alone or with another treatment, in people with advanced solid cancers that have stopped responding to standard care. It aims to see how well it works and how safe it is, including whether it can be used when treatment options are limited.
Hackensack, New JerseyAges 18 years+ - NCT05315167RecruitingPhase 1/Phase 2
Study drug PRJ1-3024 for advanced solid tumors
This trial tests how safe PRJ1-3024 is and how the body handles it, and it also looks for early signs that it can shrink advanced solid tumors. It may help people whose cancer can’t be treated with standard options.
Zhengzhou, HenanAges 18 years+ - NCT05384626RecruitingPhase 1/Phase 2
Study of an ALK-targeted drug for ALK-positive lung cancer
This early-stage study tests neladalkib (NVL-655), a medicine designed to attack ALK-positive cancer. It may help people with advanced ALK-mutated or ALK-rearranged solid tumors, especially ALK-positive non-small cell lung cancer.
Orange, CaliforniaAges 12 years+ - NCT05423262RecruitingPhase 1/Phase 2
TRK-950 for advanced solid tumors that standard treatment can’t control
This trial tests TRK-950 in people with advanced (locally advanced or metastatic) solid tumors when standard treatments have stopped working or aren’t available. It may help by trying a new treatment approach when current options are limited.
Nagoya, Aichi-kenAges 18 years+ - NCT05468359RecruitingPhase 1/Phase 2
Testing four medicines in children and teens with hard-to-treat tumors
This early-phase trial studies how safe and effective a combination of four medicines is for children and teens with certain solid tumors that have come back or cannot be controlled with standard treatment. It may help by improving tumor control, while also carefully tracking side effects.
Germantown, TennesseeAges Up to 30 years - NCT05481502Recruiting
Study looks at immune markers after cell therapy
This study collects immune and tumor-related samples to learn what predicts response to adoptive cell therapy (a treatment using immune cells). If you (or your child) are eligible, you may help researchers understand who benefits and why.
Villejuif, Val De MarneAges 2 years+ - NCT05490472RecruitingPhase 1/Phase 2
Study drug for advanced solid tumors that stopped responding
This early study tests a new medicine (JAB-2485) in adults with advanced solid tumors (cancers that have spread or grown locally). You may join to see if it can shrink tumors or control the disease when other treatments haven’t worked or weren’t tolerated.
Detroit, MichiganAges 18 years+ - NCT05518253RecruitingPhase 1
CAR-T treatment for CD70-positive advanced solid tumors
This trial tests a lab-made immune therapy (CAR-T) that targets a protein called CD70 found on some advanced cancers. It’s designed for people whose solid tumors have spread and no standard treatments have worked or weren’t tolerated.
Hangzhou, ZhejiangAges 18 years+ - NCT05525858Recruiting
Genomic testing–guided treatment for advanced solid tumors
This study uses your tumor’s genetic test results to help match you to the most suitable treatment when standard options have failed or don’t exist. It may help by targeting therapies based on specific gene changes found in your cancer.
Bucheon-siAges 19 years+
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for solid tumor?
- Yes. Clin2 currently lists 1,689 recruiting solid tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a solid tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a solid tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.